PT-141 (Bremelanotide): Mechanism & Scientific Evidence

PT-141, also known as Bremelanotide, is a cyclic synthetic analogue of α-MSH (Alpha-Melanocyte Stimulating Hormone), derived from Melanotan II. It acts as an agonist of melanocortin MC3-R and MC4-R receptors in the central nervous system. It was approved by the FDA in 2019 (Vyleesi®) for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. Its mechanism of action is completely distinct from PDE5 inhibitors.

PT-141 crosses the blood-brain barrier and activates MC3-R and MC4-R receptors in the hypothalamus, especially in the paraventricular nucleus (PVN). MC4-R activation triggers dopaminergic and noradrenergic cascades in mesolimbic circuits (motivation/reward) and stimulates central nitric oxide (NO) production, which facilitates genital response via spinal and autonomic pathways. This mechanism is distinct and complementary to PDE5 inhibitors (peripheral action).

Sildenafil and tadalafil are PDE5 inhibitors that act peripherally, increasing local nitric oxide and promoting vasodilation — they facilitate physical response but do not modulate desire. PT-141 acts centrally via melanocortin receptors in the CNS, modulating sexual desire and psychological arousal. These are non-overlapping mechanisms that are potentially complementary for different components of sexual dysfunction, as described in clinical literature.

Yes. PT-141 (bremelanotide) was approved by the FDA in June 2019 under the brand name Vyleesi® for treatment of acquired, generalized Hypoactive Sexual Desire Disorder (HSDD) in premenopausal women. It is the second FDA-approved drug for HSDD (after flibanserin, 2015) and the first with a central mechanism of action via melanocortin agonism.

The RECONNECT phase 3 trials enrolled 1,247 premenopausal women. Reported results: statistically significant reduction in distress related to low desire (FSDS-DAO scale) and increase in the FSFI desire domain versus placebo. The 52-week open-label extension (N=684) confirmed sustained effects with no new safety signals (PMID: 31599847). Independent reviews assessed the magnitude of effects as clinically modest (PMID: 36809187).

The most common adverse effects reported in RECONNECT trials were: nausea (40.4%), flushing/facial flushing (20.6%), headache (12%) and injection site pain. Prescribing guidelines recommend no more than 1 dose in 24 hours and no more than 8 doses per month. Discontinue if no benefit after 8 weeks of use. Long-term safety data (52 weeks) showed no new signals (PMID: 31599847).

Phase II studies evaluated bremelanotide in men with erectile dysfunction, including non-responders to PDE5 inhibitors. Phase II results were promising, showing improved erection via central mechanism (MC4-R/hypothalamic NO). However, PT-141 is NOT FDA-approved for male erectile dysfunction. Use in men is considered off-label. Assessment by a sexual health specialist is required (PMID: 31893927).

PT-141/Vyleesi® is administered via subcutaneous (SC) self-injection approximately 45 minutes before sexual activity, as needed. The approved dose is 1.75 mg SC. It should not be used more than once in 24 hours or more than 8 times per month. Unlike daily-use medications, it is administered only when needed (on-demand).

Biological plausibility for PT-141 + Kisspeptin combination is based on distinct central mechanisms: PT-141 acts via hypothalamic MC3-R/MC4-R (desire/arousal, independent of gonadal hormones); Kisspeptin acts via KissR1/GPR54 in the arcuate nucleus, modulating the HPG axis (LH, FSH, GnRH) and influencing libido via steroidogenesis. The theoretical combination would address multiple neuroendocrine levels of sexuality. No clinical trials have evaluated this combination.

In Brazil, bremelanotide (Vyleesi®) does not have ANVISA approval as a medication. In Europe, the EMA (European Medicines Agency) evaluated and did not approve bremelanotide, considering that the benefits did not sufficiently outweigh the risks. The product is approved only in the USA (FDA, 2019) for premenopausal women with HSDD. Use in other countries is considered off-label.

Yes. PT-141 (bremelanotide) is a synthetic cyclic heptapeptide, structurally derived from Melanotan II (MT-II), which is itself an analogue of α-MSH (13 amino acids). The cyclic structure of PT-141 provides greater metabolic stability compared to native α-MSH. It is a low molecular weight peptide (~1,025 Da) that crosses the blood-brain barrier by mechanisms not fully elucidated.

Reported contraindications include: pre-existing uncontrolled cardiovascular hypertension (bremelanotide may transiently elevate blood pressure after administration). Should be avoided in patients with a history of cardiovascular events or severe cardiovascular disease. Use with alcohol showed no clinically significant interactions in studies. Medical evaluation is mandatory before initiation, per prescribing guideline recommendations (PMID: 31893927). Do not use in pregnancy.